Drugs / Recombinant Human Hyaluronidase (rHu)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07161414 Background | Nov 2025 → Jul 2027 expected | cancer | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Hyaluronidase (rHu) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07161414 ↗ |
| Route | Subcutaneous | “rHu administered subcutaneously.” NCT07161414 ↗ |